Medical interventions for primary open angle glaucoma and ocular hypertension

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Vass, Clemens ^a   Hirn, C ^b   Sycha, T ^b   Findl, O ^b   Sacu, S ^b   Bauer, P ^b   Schmetterer, L ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Adrenergic beta antagonists *therapeutic use ; Antihypertensive agents *therapeutic use ; Glaucoma, open angle *drug therapy ; Humans; Ocular hypertension *drug therapy ; Randomized controlled trials as topic

Indexed keywords

ADRENALIN; BETAXOLOL; BRIMONIDINE; CARTEOLOL; DORZOLAMIDE; LEVOBUNOLOL; PILOCARPINE; PLACEBO; TIMOLOL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 44949185496     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003167.pub3     Document Type: Review

References (76)

1. Alexander 1988 {published data only} Alexander DW, Berson FG, Epstein DL. A clinical trial of timolol and epinephrine in the treatment of primary open-angle glaucoma. Ophthalmology 1988;95(2):247-51.
2. Collignon-Brach 1992 {published data only} Collignon-Brach J. Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Current Eye Research 1992;11(1):1-3.
3. Collignon-Brach 1994 {published data only} Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Survey of Ophthalmology 1994;38 (Suppl 1):S149-55.
4. Drance 1998 {published data only} Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. Journal of Glaucoma 1998;7(4):247-52.
5. EGPS 2005 {published data only} The European Glaucoma Prevention Study. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology 2002;109(9):1612- 21.
6. *The European Glaucoma Prevention Study Group. Results of the European glaucoma prevention study. Ophthalmology 2005;112(3): 366-75.
7. Epstein 1989 {published data only} Epstein DL, Krug JH, Hertzmark E, Remis LL, Edelstein DJ. A long-term clinical trial of timolol versus no treatment in the management of glaucoma suspects. Ophthalmology 1989;96(10):1460-7.
8. Fama 1996 {published data only} Fama F, Santamaria S. Comparison of the ocular effects of three beta-blockers: timolol, carteolol, and betaxolol. Annals of Ophthalmology 1996;28(5):317-20.
9. Flammer 1992 {published data only} Flammer J, Kitazawa Y, Bonomi L, Mills B, Fsadni M, Dorigo MT, et al.Influence of carteolol and timolol on IOP and visual fields in glaucoma: a multi-center, double-masked, prospective study. European Journal of Ophthalmology 1992;2(4): 169-74.
10. Geyer 1988 {published data only} Geyer O, Lazar M, Novack GD, Lue JC, Duzman E. Leovbunolol compared with timolol for the control of elevated intraocular pressure. Annals of Ophthalmology 1986;18(10):289-92.
11. *Geyer O, Lazar M, Novack GD, Shen D, Eto CY. Levobunolol compared with timolol: a four-year study. British Journal of Ophthalmology 1988;72(12):892-6.
12. Heijl 2000 {published data only} Bengtsson B, Heijl A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. Journal of Glaucoma 2005;14(2):135-8.
13. Bengtsson B, Heijl A. Diurnal IOP fluctuation: Not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension. Graefe's Archive for Clinical & Experimental Ophthalmology 2005;243(6):513-8.
14. *Heijl A, Bengtsson B. Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial. Graefe's Archive for Clinical and Experimental Ophthalmology 2000;238(11):877-83.
15. Kaiser 1994 {published data only} Kaiser HJ, Flammer J, Stümpfig D, Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Survey of Ophthalmology 1994;38(Suppl 1):S156-60.
16. Kamal 2003 {published data only} Kamal D, Garway-Heath D, Ruben S, O'Sullivan F, Bunce C, Viswanathan A, et al.Results of the betaxolol versus placebo treatment trial in ocular hypertension. Graefes Archive for Clinical & Experimental Ophthalmology 2003;241(3):196-203.
17. Kass 1989 {published data only} Kass MA. Five-year follow-up study of timolol in patients at moderate risk of developing open-angle glaucoma. Chibret International Journal of Ophthalmology 1990;7(1):5-8.
18. *Kass MA. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: A five-year, randomized, double-masked, clinical trial. Transactions of the American Ophthalmological Society 1989;87:598-618.
19. Kass MA, Gordon MO, Hoff MR, Parkinson JM, Kolker AE, Hart WM, et al.Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Archives of Ophthalmology 1989;107(11):1590-8.
20. Kass 2002 {published data only} Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al.The ocular hypertension treatments study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology 2002;120(6):701-13.
21. Kitazawa 1990 {published data only} Kitazawa Y. The effect of timolol on topographic features of the optic disk in ocular hypertension. Chibret International Journal of Ophthalmology 1990;7(1):14-7.
22. Leblanc 1998 {published data only} *Leblanc R, Brimonidine Study Group 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998;105(10):1960-7.
23. Melamed S, David R, Brimonidine Study Group 2. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clinical Therapeutics 2000;22(1): 103-11.
24. Novack 1989 {published data only} Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman E. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Archives of Ophthalmology 1985;103 (3):379-82.
25. Cinotti A, Cinotti D, Grant W, Jacobs I, Galin M, Silverstone D, et al.Levobunolol vs timolol for open-angle glaucoma and ocular hypertension. American Journal of Ophthalmology 1985;99(1):11-7.
26. Novack G, The Levobunolol Study Group. Levobunolol. A beta-adrenoceptor antagonist effective in the long-term treatment of glaucoma. Ophthalmology 1985;92(9):1271-6.
27. *Novack GD, The Levobunolol Study Group. Levobunolol: a four-year study of efficacy and safety in glaucoma treatment. Ophthalmology 1989;96(5):642-5.
28. Ober M, Scharrer A, David R, Biedner B-Z, Novack GD, Lue JC, et al.Long-term ocular hypotensive effect of levobunolol: results of a one-year study. British Journal of Ophthalmology 1985;69(8):593-9.
29. Ravalico 1994 {published data only} Ravalico G, Salvetat L, Toffoli G, Pastori G, Croce M, Parodi MB. Ocular hypertension: a follow-up study in treated and untreated patients. New Trends in Ophthalmology 1994;9(2):97-101.
30. Schulzer 1991 {published data only} Chauhan BC, Drance SM, Douglas GR. The effect of long-term intraocular pressure reduction on the differential light sensitivity in glaucoma suspects. Investigative Ophthalmology and Visual Science 1988;29(10):1478-85.
31. *Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology 1991;98(3):301-7.
32. Schuman 1997 {published data only} Schuman JS, Brimonidine Study Group. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Survey of Ophthalmology 1996;41(Suppl 1):S27-S37.
33. *Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K, Brimonidine Study Group. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Archives of Ophthalmology 1997;115 (7):847-52.
34. Schwartz 1995 {published data only} Schwartz B, Lavin P, Takamoto T, Araujo DF, Smits G. Decrease of optic disc cupping and pallor of ocular hypertensives with timolol therapy. Acta Ophthalmologica Scandinavica 1995;73(Suppl 215):5-21.
35. Schwartz B, Takamoto T, Lavin P, Smits G. Increase of retinal nerve fiber thickness in ocular hypertensives with timolol therapy. Acta Ophthalmologica Scandinavica 1995;73(Suppl 215):22-32.
36. Sponsel 1987 {published data only} Dallas NL, Sponsel WE, Hobley AJ. A comparative evaluation of timolol maleate and pilocarpine in the treatment of chronic open angle glaucoma. Eye 1988;2(Pt 3):243-9.
37. Sponsel WE. Timolol vs pilocarpine in open angle glaucoma: the observation of significant differences in visual field response in patients with clinically equivalent IOP control. Chibret International Journal of Ophthalmology 1987;5(3):50-6.
38. Tsai 2005 {published data only} Tsai JC, Chang HW. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: A prospective, unmasked study. Journal of Ocular Pharmacology and Therapeutics 2005;21(6):475-82.
39. Vogel 1992 {published data only} Vogel R, Crick RP, Mills KB, Reynolds PM, Sass W, Clineschmidt CM, et al.Effect of timolol versus pilocarpine on visual field progression in patients with primary open-angle glaucoma. Ophthalmology 1992;99(10):1505-11.
40. Watson 2001 {published data only} *Watson PG, Barnet MF, Parker V, Haybittle J. A 7-year prospective comparative study of three topical beta-blockers in the management of primary open angle glaucoma. British Journal of Ophthalmology 2001;85(8):962-8.
41. Watson PG, Barnett MF, Parker V, Haybittle J, Fellman R. A 7-year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Evidence Based Eye Care 2002;3(3):144-5.
42. Wishart 1992 {published data only} Wishart P K, Batterbury M. Ocular hypertension: correlation of anterior chamber angle width and risk of progression to glaucoma. Eye 1992;6(Pt 3):248-56.
43. Araie 2003 Araie M, Azuma I, Kitazawa Y. Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients. Japanese Journal of Ophthalmology 2003;47(2):199-207.
44. EMGT 1999 Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 2002;120(10):1268-79.
45. Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC. Treatment and vision-related quality of life in early manifest glaucoma trial. Ophthalmology 2005;112(9):1505-13.
46. *Leske MC, Heijl A, Hyman L, Bengsson B, Early Manifest Glaucoma Trial. Early manifest glaucoma trial. Design and baseline data. Ophthalmology 1999;106(11):2144-53.
47. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Current Opinion in Ophthalmology 2004;15(2):102-6.
48. Holmin 1988 Holmin C, Thorburn W, Krakau CE. Treatment versus no treatment in chronic open angle glaucoma. Acta Ophthalmologica 1988;66(2): 170-3.
49. Vainio 1999 *Vainio Jylha E, Vuori ML. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Graefes Archive for Clinical& Experimental Ophthalmology 1999;237 (2):100-4.
50. Vainio-Jylhä E, Vuori ML, Nummelin K. Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients. Acta Ophthalmologica Scandinavica 2002;80(5):495-500.
51. CGSG 2006 Canadian Glaucoma Study Group. Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. Canadian Journal of Ophthalmology 2006;41(5):566-75.
52. Hommer 2007 Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03% timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. European Journal of Ophthalmology 2007;17(1):53-62.
53. Kanno 2006a Kanno M, Araie M, Masuda K, Takase M, Kitazawa Y, Shiose Y, et al.Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Arzneimittel-Forschung 2006;56 (11):729-34.
54. Kanno 2006b Kanno M, Araie M, Masuda K, Takase M, Kitazawa Y, Shiose Y, et al.Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Part 2. Arzneimittel-Forschung 2006;56(12): 820-5.
55. Noecker 2007 Noecker RJ, Awadallah NS, Kahook MY. Travoprost 0.004% imolol 0.5% fixed combination. Drugs of Today 2007;43(2): 77-83.
56. Schmier 2006 Schmier JK, Halpern MT, Covert DW, Robin AL. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. Current Medical Research & Opinion 2006;22(9):1737-43.
57. Sherwood 2006 Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, et al.Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vsmonotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Archives of Ophthalmology 2006;124(9):1230-8.
58. Whitson 2006 Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, et al.The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006;113(8):1333-9.
59. Armaly 1980 Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, et al.Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Archives of Ophthalmology 1980;98(12):2163- 71.
60. Caprioli 1998 Caprioli J. The treatment of normal-tension glaucoma. American Journal of Ophthalmology 1998;126(4):578-81.
61. CNTGS 1998 Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. American Journal of Ophthalmology 1998;126(4): 498-505.
62. Diggory 1998 Diggory P, Cassels-Brown A, Vail A, Hillman JS. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. British Journal of Ophthalmology 1998;82(2):146-9.
63. Gandolfi 2005 Gandolfi SA, Ghetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Archives of Ophthalmology 2005;123(1):135-8.
64. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
65. Higgins 2006a Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006; Section 6]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
66. Higgins 2006b Higgins JPT, Green S, editors. Collecting data. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006; Section 7]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
67. Maier 2005 Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter Y. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomized controlled trials. BMJ 2005;331(7509):134.
68. Ontoso 1997 Aguinaga-Ontoso I, Guillen-Grima F, Aguinaga-Ontoso E, Fernandez-Fernandez LR. Does medical treatment of mild intraocular hypertension prevent glaucoma?. European Journal of Epidemiology 1997;13(1): 19-23.
69. Quigley 1983 Quigley HA, Hohmann RM, Addicks EM, Massof RW, Green W. Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. American Journal of Ophthalmology 1983;95(5):673-91.
70. Quigley 2005 Quigley HA, Miglior S, Pfeiffer N, Zeyen T, Cunha-Vaz J, Torri V, et al.European glaucoma prevention study. Authors' reply. Ophthalmology 2005; Vol. 112, issue 9:1642-5.
71. Rossetti 1993 Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Torri V, Liberati A. Randomized clinical trials on medical treatment of glaucoma: are they appropriate to guide clinical practice?. Archives of Ophthalmology 1993;111(1):96-103.
72. Schulzer 1990 Schulzer M, Drance SM, Carter CJ, Brooks DE, Douglas DE, Lau W. Biostatistical evidence for two distinct chronic open-angle glaucoma populations. British Journal of Ophthalmology 1990;74(4):196-200.
73. Sycha 2005 Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, et al.Interventions for normal tension glaucoma. Cochrane Database of Systematic Reviews 2005, Issue 1.Art. No.: CD002222.. DOI: 10.1002/14651858.CD002222..
74. Takamoto 1985 Takamoto T, Schwartz B. Reproducibility of photogrammetric optic disc cup measurements. Investigative Ophthalmology and Visual Science 1985;26(6):814-7.
75. Waldock 2000 Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. British Journal of Ophthalmology 2000; 84(7):710-3.
76. Wiysonge 2006 Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al.Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD002003. DOI: 10.1002/14651858.CD002003.pub2.